Neo Ivy Capital Management grew its position in Sotera Health (NASDAQ:SHC - Free Report) by 144.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,546 shares of the company's stock after buying an additional 62,420 shares during the quarter. Neo Ivy Capital Management's holdings in Sotera Health were worth $1,443,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. raised its position in Sotera Health by 6.0% during the fourth quarter. Xponance Inc. now owns 17,495 shares of the company's stock valued at $239,000 after purchasing an additional 989 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after buying an additional 1,140 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Sotera Health by 37.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after buying an additional 1,640 shares during the last quarter. Bank of Montreal Can boosted its stake in Sotera Health by 10.6% in the fourth quarter. Bank of Montreal Can now owns 18,184 shares of the company's stock valued at $249,000 after buying an additional 1,740 shares in the last quarter. Finally, Quarry LP acquired a new stake in Sotera Health in the fourth quarter valued at about $28,000. Institutional investors own 91.03% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on SHC shares. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and increased their target price for the stock from $14.00 to $17.00 in a report on Monday, May 5th. Barclays dropped their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, Piper Sandler cut their target price on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.80.
Get Our Latest Analysis on Sotera Health
Sotera Health Trading Down 1.9%
NASDAQ:SHC traded down $0.23 during trading hours on Wednesday, hitting $12.20. 826,297 shares of the company were exchanged, compared to its average volume of 1,201,654. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of 48.80 and a beta of 1.88. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The company has a fifty day simple moving average of $11.66 and a 200 day simple moving average of $12.68. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91.
Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company had revenue of $254.52 million for the quarter, compared to analyst estimates of $245.56 million. During the same period in the previous year, the firm earned $0.13 earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. Sell-side analysts expect that Sotera Health will post 0.61 EPS for the current fiscal year.
About Sotera Health
(
Free Report)
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Further Reading
Before you consider Sotera Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sotera Health wasn't on the list.
While Sotera Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
